摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴甲基-2,1,3-苯并二唑 | 32863-31-3

中文名称
5-溴甲基-2,1,3-苯并二唑
中文别名
5-溴甲基苯并呋咱
英文名称
5-(bromomethyl)benzofurazan
英文别名
5-(bromomethyl)benzo[c][1,2,5]oxadiazole;5-(bromomethyl)-2,1,3-benzoxadiazole
5-溴甲基-2,1,3-苯并二唑化学式
CAS
32863-31-3
化学式
C7H5BrN2O
mdl
MFCD00174369
分子量
213.033
InChiKey
BUJFLTNYWUEROF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    77 °C
  • 沸点:
    283.5±32.0 °C(Predicted)
  • 密度:
    1.742±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2934999090
  • 危险品运输编号:
    UN 3261
  • 包装等级:
    II
  • 危险类别:
    8
  • 危险性防范说明:
    P260,P264,P271,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P403+P233,P405,P501
  • 危险性描述:
    H335,H314

SDS

SDS:f548baba5e3c2e3adfdbb62e0aa98c41
查看
Name: 5-(Bromomethyl)-2 1 3-benzoxadiazole 97% Material Safety Data Sheet
Synonym: 5-(Bromomethyl)benzofuraza
CAS: 32863-31-3
Section 1 - Chemical Product MSDS Name:5-(Bromomethyl)-2 1 3-benzoxadiazole 97% Material Safety Data Sheet
Synonym:5-(Bromomethyl)benzofuraza

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
32863-31-3 5-(Bromomethyl)-2,1,3-benzoxadiazole 97% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 32863-31-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H5BrN2O
Molecular Weight: 213

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Reducing agents, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 32863-31-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-(Bromomethyl)-2,1,3-benzoxadiazole - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 32863-31-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 32863-31-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 32863-31-3 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

5-溴甲基-2,1,3-苯并二唑是一种用于研究的化合物。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-溴甲基-2,1,3-苯并二唑4-乙烯基吡啶盐酸N,N-二异丙基乙胺 作用下, 以 四氢呋喃甲醇乙醇 为溶剂, 反应 85.0h, 生成 6-((benzo[c][1,2,5]oxadiazol-5-yl)methoxyimino)-2-methoxyestradiol
    参考文献:
    名称:
    WO2008/109936
    摘要:
    公开号:
  • 作为产物:
    描述:
    4-氟-3-硝基苯甲醛甲醇 、 sodium tetrahydroborate 、 sodium azide 、 四溴化碳三苯基膦 作用下, 以 四氢呋喃乙醇二甲基亚砜甲苯 为溶剂, 反应 12.0h, 生成 5-溴甲基-2,1,3-苯并二唑
    参考文献:
    名称:
    联苯类化合物及其制备方法和医药用途
    摘要:
    本发明公开了联苯类化合物及其制备方法和医药用途,该联苯类化合物结构如式(I)或式(II)所示,本发明的联苯类化合物或其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体、代谢产物、代谢前体、前药或溶剂化物是PD‑L1抑制剂,对PD‑1和PD‑L1蛋白‑蛋白相互作用具有显著的抑制作用,因而可应用于制备PD‑L1抑制剂,并应用于制备预防或治疗肿瘤、自身免疫性疾病、器官移植排斥、感染性疾病和炎症性疾病的免疫调节剂类药物;
    公开号:
    CN111909108B
点击查看最新优质反应信息

文献信息

  • Sulfonamide peri-substituted bicyclics for occlusive artery disease
    申请人:Singh Jasbir
    公开号:US20060079520A1
    公开(公告)日:2006-04-13
    Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:
    酰基磺酰胺,带有周取代的融合双环环化合物,用于治疗或预防前列腺素介导的疾病或症状。这些化合物的一般公式为 代表性示例是:
  • Quinolines useful in treating cardiovascular disease
    申请人:Collini D. Michael
    公开号:US20050131014A1
    公开(公告)日:2005-06-16
    This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.
    本发明提供了式I化合物的用途,它们在治疗或抑制LXR介导的疾病中是有用的。
  • Non-steroid progesterone receptor agonist and antagonist and compounds
    申请人:Ligand Pharmaceuticals Incorporated
    公开号:US05808139A1
    公开(公告)日:1998-09-15
    Non-steroidal compounds which are high affinity, high specificity ligands for progesterone receptors are disclosed. The compounds include synthetic derivatives of cyclocymopol and its diastereomers, spectroscopically and chromatographically pure (3R)-cyclocymopol monomethyl ether, which functions as a progesterone receptor antagonist, and spectroscopically and chromatographically pure (3S)-cyclocymopol monomethyl ether, which functions as a progesterone receptor agonist. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by progesterone receptors and for treating patients requiring progesterone receptor agonist or antagonist therapy.
    公开了与孕酮受体具有高亲和力、高特异性的非甾体化合物。这些化合物包括环状赛波尔的合成衍生物及其对映异构体,光谱和色谱纯(3R)-环状赛波尔甲醚,其作为孕酮受体拮抗剂,以及光谱和色谱纯(3S)-环状赛波尔甲醚,其作为孕酮受体激动剂。还公开了利用所述化合物调节孕酮受体介导的过程以及治疗需要孕酮受体激动剂或拮抗剂治疗的患者的方法。
  • Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
    申请人:Levin I. Jeremy
    公开号:US20060211730A1
    公开(公告)日:2006-09-21
    This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.
    这项发明提供了具有结构的Formula I的化合物,这些化合物在治疗由TNF-α介导的疾病或紊乱方面非常有用,如关节炎(类风湿关节炎(RA),幼年RA,银屑病性关节炎,骨关节炎等),肿瘤转移,组织溃疡,异常伤口愈合,牙周病,骨病,糖尿病(胰岛素抵抗)和HIV感染,强直性脊柱炎,银屑病,败血症,多发性硬化,克罗恩病,退行性软骨丢失,哮喘,特发性肺纤维化,血管炎,系统性红斑狼疮,肠易激综合征,急性冠状动脉综合征,丙型肝炎,虚弱,慢性阻塞性肺病,中风或2型糖尿病的缓解症状。该发明还提供了使用这些化合物的方法。
  • [EN] PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV<br/>[FR] COMPOSÉS PYRROLOPYRIDINONES ET MÉTHODES DE TRAITEMENT DU VIH
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2013043553A1
    公开(公告)日:2013-03-28
    Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).
    提供了这些化合物及其药用盐,它们的药物组合物,它们的制备方法,以及它们用于治疗由逆转录病毒家族成员介导的病毒感染,如人类免疫缺陷病毒(HIV)的用途。
查看更多

同类化合物

重氮二硝基苯酚 达罗地平 苯并芙咱-5-硼酸频那醇酯 苯并氧化呋咱-5-羧酸 苯并呋扎-5-甲腈 苯并呋喃-5-磺酰氯 苯并呋喃-5-甲酸乙酯 苯并呋喃 苯并呋咱-5-羧酸乙酯 苯并呋咱-5-羧酸 苯并呋咱-5-碳酰氯 苯并呋咱 苯并二唑-4-甲醛 苯呋咱-5-三氟硼酸钾 硝基氨基吡咯烷苯并恶嗪 哌嗪酮,6-甲基-5-硫代-,(R)-(9CI) 去甲基伊拉地平 伊拉地平内酯 伊拉地平EP杂质A 伊拉地平 乙酮,1-[5-(丁基氨基)-2-羟基苯基]- NBD-双十六胺 N-[12-[((7-硝基-2-1,3-苯并恶二唑-4-基)氨基]十二烷酰基]-D-赤型-鞘氨醇 N-7-(4-硝基苯并-2-氧代-1,3-二氮唑)-omega-氨基己酸beta-(N-三甲基铵)乙酯 N-(7-硝基苯并-2-氧杂-1,3-二氮唑-4-基)磷脂酰乙醇胺 N-(3-氯-5-氟苯基)-4-硝基-2,1,3-苯并恶二唑-5-胺 N-(2-吗啉基乙基)-7-硝基-2,1,3-苯并恶二唑-4-胺 N,N-二甲基-7-硝基苯并呋咱-4-胺 N,N-二丁基-7-硝基-4-苯并呋咱胺 N'-[5-[[4-[5-(乙酰基-羟基氨基)戊基氨基]-4-氧代丁酰基]-羟基氨基]戊基]-N-羟基-N-[5-[(4-硝基-2,1,3-苯并恶二唑-7-基)氨基]戊基]丁二酰胺 8-异米索前列醇 7-肼-N,N-二-4-苯并呋咱磺 7-硝基-N-[2-(2-吡啶基二硫代)乙基]-2,1,3-苯并恶二唑-4-胺 7-硝基-1-氧代-2,1,3-苯并恶二唑-1-鎓 7-甲氧基-2,1,3-苯并恶二唑-4-磺酰氯 7-氯苯并[c][1,2,5]噁二唑-4-胺 7-氯-N,N-二乙基-4-硝基-2,1,3-苯并恶二唑-5-胺 7-氯-4-硝基-5-哌啶基-2,1,3-苯并噁二唑 7-氯-4-硝基-2,1,3-苯并噁二唑1-氧化 7-氯-2,1,3-苯并噁二唑-4-磺酸 7-氟苯呋咱-4-磺酰胺 7-氟苯呋咱-4-硫氨 7-氟-2,1,3-苯并恶二唑-4-磺酰氯 7-哌啶-1-基-2,1,3-苯并恶二唑-4-胺 7-吗啉-4-基苯并[1,2,5]恶二唑-4-基胺 6-溴苯并[c][1,2,5]噁二唑1-氧化物 6-氟-2,1,3-苯并恶二唑-5-胺 6-[[7-(N,N-二甲氨基磺酰)-2,1,3-苯并恶二唑-4-基]氨基]己酸琥珀酰亚胺酯 6-[(7-硝基-2,1,3-苯并恶二唑-4-基)氨基]己酸 6,7-二氢-1,2,3,10-四甲氧基-7-[甲基(7-硝基-2,1,3-苯并恶二唑-4-基)氨基]-(7S)-苯并[a]庚搭烯-9(5H)-酮